Compare Figs Inc (FIGS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs IDEXX Laboratories, Inc. — how do they compare? Figs Inc trades at $10.15 (market cap $1.66B), while IDEXX Laboratories, Inc. trades at $574.43 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 26.5× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| FIGS | IDXX | |
|---|---|---|
Market Cap | $1.66B | $43.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $766.68 |
52-Week Low | $5.81 | $514.61 |
Enterprise Value | $1.44B | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $10.08, up 3.7% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $631.1M in 2025 (Zacks Investment Research, 2026-05-07), but net cash flow remains negative. Analyst consensus is Buy with a $19.50 target, though technical indicators show selling pressure.
Outlook hinges on global expansion and margin management amid cost pressures. Risks include competitive threats and volatile cash flows, but strong customer growth and premium positioning offer upside if execution improves.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
